Collegium Pharmaceutical Inc. (NASDAQ:COLL)’s share price hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $11.32 and last traded at $11.35, with a volume of 48,801 shares changing hands. The stock had previously closed at $11.86.

A number of equities analysts have issued reports on the company. Zacks Investment Research raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday, July 26th. Piper Jaffray Cos. reaffirmed a “buy” rating and issued a $27.00 target price (up from $26.00) on shares of Collegium Pharmaceutical in a research report on Thursday, June 23rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 target price (up from $28.00) on shares of Collegium Pharmaceutical in a research report on Thursday, May 26th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $29.25.

The stock’s market capitalization is $270.91 million. The firm’s 50 day moving average price is $12.87 and its 200 day moving average price is $16.38.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.68) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.60) by $0.08. Analysts predict that Collegium Pharmaceutical Inc. will post ($3.25) earnings per share for the current fiscal year.

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.